Designing HIV vaccination policies: Subtypes and cross-immunity

Interfaces

Volumn 28, Issue 3, 1998, Pages 167-190

  Porco, Travis C ^a   Blower, Sally M ^b  

^a S Francisco Dept of Public Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0041182412     PISSN: 00922102     EISSN: None     Source Type: Journal    
DOI: 10.1287/inte.28.3.167     Document Type: Article

References (41)

1. Anderson, R. M. and May, R. M. 1991, Infectious Diseases of Humans: Dynamics and Control, Oxford University Press, Oxford, England.
2. Artenstein, A. W.; VanCott, T. C.; Mascola, J. R.; Carr, J. K.; Hegerich, P. A.; Gay wee, J.; Sanders-Buell, E.; Robb, M. L.; Dayhoff, D. E.; Thitivichianlert, S.; Nitayaphan, S.; McNeil, J. G.; Birx, D. L.; Michael, R. A.; Burke, D. S.; and McCutchan, F. E. 1995, "Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans," Journal of Infectious Diseases, Vol. 171, No. 4, pp. 805-810.
3. Bloom, B. R. 1996, "A perspective on AIDS vaccines," Science, Vol. 272, No. 5270, pp. 1888-1890.
4. Blower, S. M. and McLean, A. R. 1994, "Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco," Science, Vol. 265, No. 5177, pp. 1451-1454.
5. Blower, S. M. and McLean, A. R. 1995, "AIDS: Modeling epidemic control," Science, Vol. 267, No. 5202, pp. 1250-1253.
6. Burke, D. S. and McCutchan, F. E. 1997, "Global distribution of human immunodeficiency virus-1 clades," in AIDS: Biology, Diagnosis, Treatment and Prevention, eds. V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, Lippincott-Raven, Philadelphia, Pennsylvania, pp. 119-126.
7. Cohen, J. 1994, "Are researchers racing toward success, or crawling?" Science, Vol. 265, No. 5177, pp. 1373-1375.
8. Ferrari, G.; Humphrey, W.; McElrath, M. J.; Excler, J.-L.; Duliege, A.-M.; Clements, M. L.; Corey, L. C.; Bolognesi, D. P.; and Weinhold, K. J. 1997, "Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers," Proceedings of the National Academy of Science of the United States of America, Vol. 94, No. 4, pp. 1396-1401.
9. Fisher, A. G.; Ensoli, B.; Looney, D.; Rose, A.; Gallo, R. C.; Saag, M. S.; Shaw, G. M.; Hahn, B. H.; and Wong-Staal, F. 1988, "Biologically diverse molecular variants within a single HIV-1 isolate," Nature, Vol. 334, No. 6181, pp. 444-447.
10. Grady, C. and Kelly, G. 1996, "State of the science: HIV vaccine development," Nursing Clinics of North America, Vol. 31, No. 1, pp. 25-39.
11. Grant, R. M.; Wiley, J. A.; and Winkelstein, W. 1987, "Infectivity of the human immunodeficiency virus: Estimates from a prospective study of homosexual men," Journal of Infectious Diseases, Vol. 156, No. 1, pp. 189-193.
12. Horn, R. A. and Johnson, C. R. 1985, Matrix Analysis, Cambridge University Press, Cambridge, England.
13. Hu, D. J.; Dondero, T. J.; Rayfield, M. A.; George, J. R.; Schochetman, G.; Jaffe, H. W.; Luo, C. C; Kalish, M. L.; Weniger, B. G.; and Pau, C. P. 1996, "The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention," Journal of the American Medical Association, Vol. 275, No. 3, pp. 210-216.
14. Kalish, M. L.; Baldwin, A.; Raktham, S.; Wasi, C.; Luo, C.-C.; Schochetman, G.; Mastro, T. D.; Young, N.; Vanichseni, S.; Rubsamen-Waigmann, H.; von Breisen, H.; Mullins, J. I.; Delwart, E.; Herring, B.; Esparza, J.; Heyward, W. L.; and Osmanov, S. 1995, "The evolving molecular epidemiology of HlV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: Implications for HIV vaccine trials," AIDS, Vol. 9, No. 8, pp. 851-857.
15. Kanki, P.; Travers, K. U.; Mboup, S.; Hsieh, C.-C.; Marlink, R. G.; Guèye-Ndiaye, A.; Siby, T.; Thior, I.; Hernandez-Avila, M.; Sankalé, J.-L.; Ndoye, I.; and Essex, M. E. 1994, "Slower heterosexual spread of HIV-2 than HIV-1," Lancet, Vol. 343, No. 8903, pp. 943-946.
16. Kermack, W. O. and McKendrick, A. G. 1927, "A contribution to the mathematical theory of epidemics," Proceedings of the Royal Society of London, A, Vol. 115, No. 772, pp. 700-721.
17. Kuiken, C. L.; Zwart, G.; Baan, E.; Coutinho, R. A.; van den Hoek, J. A.; and Goudsmit, J. 1993, "Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic," Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, No. 19, pp. 9061-9065.
18. Kunanusont, C.; Foy, H. M.; Kreiss, J. K.; Rerks-Ngarm, S.; Phanuphak, P.; Raktham, S.; Pau, C.-P.; and Young, N. L. 1995, "HIV-1 subtypes and male-to-female transmission in Thailand," Lancet, Vol. 345, No. 8957, pp. 1078-83.
19. Levy, J. A. 1996, "HIV heterogeneity in transmission and pathogenesis," in AIDS in the World II, Global Dimensions, Social Roots, and Responses, eds. J. M. Mann and D. J. M. Tarantola, Oxford University Press, New York, pp. 177-185.
20. MacDonald, G. 1957, The Epidemiology and Control of Malaria, Oxford University Press, London, England.
21. Marlink, R.; Kanki, P.; Thior, I.; Travers, K.; Eisen, G.; Siby, T.; Traore, I.; Hsieh, C.-C.; Dia, M.; Gueye, E.-H.; Hellinger, J.; Guèye-Ndiaye, A.; Sankalé, J.-L.; Ndoye, I.; Mboup, S.; and Essex, M. 1994, "Reduced rate of disease development after HIV-2 infection as compared to HIV-1," Science, Vol. 265, No. 8903, pp. 1587-1590.
22. Mascola, J. R.; Louwagie, J.; McCutchan, F. E.; Fischer, C. L.; Hegerich, P. A.; Wagner, K. F.; Fowler, A. K.; McNeil, J. G.; and Burke, D. S. 1994, "Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype," Journal of Infectious Diseases, Vol. 169, No. 1, pp. 48-54.
23. Mascola, J. R.; Snyder, S. W.; Weislow, O. S.; Belay, S. M.; Belshe, R. B.; Schwartz, D. H.; Clements, M. L.; Dolin, R.; Graham, B. S.; Gorse, G. J.; Keefer, M. C.; McElrath, M. J.; Walker, M. C.; Wagner, K. F.; McNeil, J. G.; McCutchan, F. E.; and Burke, D. S. 1996, "Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1," Journal of Infectious Diseases, Vol. 173, No. 2, pp. 340-348.
24. Mastro, T. D.; Satten, G. A.; Nopkesorn, T.; Sangkharomya, S.; and Longini, I. M., Jr. 1994, "Probability of female-to-male transmission of HIV-1 in Thailand," Lancet, Vol. 343, No. 8891, pp. 204-207.
25. McCutchan, F.; Hegerich, P.; Brennan, T.; Phanuphak, P.; Singharaj, P.; Jugsudee, A.; Berman, P.; Gray, A.; Fowler, A.; and Burke, D. 1992, "Genetic variants of HIV in Thailand," AIDS Research and Human Retroviruses, Vol. 8, No. 11, pp. 1887-1895.
26. McCutchan, F. E.; Salminen, M. O.; Carr, J. K.; and Burke, D. S. 1996, "HIV-1 genetic diversity," AIDS, Vol. 10, Suppl. 3, pp. S13-S20.
27. McLean, A. R. 1995, "Vaccination, evolution and changes in the efficacy of vaccines: A theoretical framework," Proceedings of the Royal Society of London, Series B, Vol. 261, No. 1362, pp. 389-393.
28. McLean, A. R. and Blower, S. M. 1993, "Imperfect vaccines and herd immunity to HIV," Proceedings of the Royal Society of London, Series B, Vol. 253, No. 1336, pp. 9-13.
29. McLean, A. R. and Blower, S. M. 1995, "Modelling HIV vaccination," Trends in Microbiology, Vol. 3, No. 12, pp. 458-463.
30. Mertens, T. and Piot, P. 1997, "Global aspects of human immunodeficiency virus epidemiology: General considerations," in AIDS: Biology, Diagnosis, Treatment and Prevention, eds. V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, Lippincott-Raven, Philadelphia, Pennsylvania, pp. 103-118.
31. Osmond, D. H.; Page, K.; Wiley, J.; Garrett, K.; Sheppard, H. W.; Moss, A. R.; Schrager, L.; and Winkelstein, W. 1994, "HIV infection in homosexual and bisexual men 18 to 29 years of age: The San Francisco Young Men's Health Study," American Journal of Public Health, Vol. 84, No. 12, pp. 1933-1937.
32. Ou, C. Y.; Takebe, Y.; Weniger, B.; Luo, C. Y.; Kalish, M.; Auwant, W.; Yamazaki, S.; Gayle, H.; Young, N.; and Schochetman, G. 1993, "Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand," Lancet, Vol. 341, No. 8854, pp. 1171-1174.
33. Porco, T. C. and Blower, S. M. 1997, "HIV vaccines: Subtypes, cross-immunity, and risk behavior change," working paper.
34. Rojas, J. M.; Dopazo, J.; Najera, I.; Sánchez-Palomino, S.; Olivares, I.; Martin, M. J.; Bernai, A.; Garcia-Saiz, A.; Najera, R.; and Lopez-Galindez, C. 1994, ́Molecular epidemiology of HIV-1 in Madrid,́ Virus Research, Vol. 31, No. 3, pp. 331-342.
35. Rowe, P. M. 1996, ́HIV subtypes raise vaccine anxieties,́ Lancet, Vol. 347, No. 9001, p. 603.
36. Saag, M. S.; Hahn, B. H.; Gibbons, J.; Li, Y.; Parks, E. S.; Parks, W. P.; and Shaw, G. M. 1988, ́Extensive variation of human immunodeficiency virus type-1 in vivo,́ Nature, Vol. 334, No. 6181, pp. 440-443.
37. Sánchez-Palomino, S.; Dopazo, J.; Olivares, I.; Martin, M. J.; and Löpez-Galíndez, C. 1995, "Primary genetic characterization of HIV-1 isolates from WHO-sponsored vaccine evaluation sites by the RNase-A mismatch method," Virus Research, Vol. 39, No. 2-3, pp. 251-259.
38. Soto-Ramirez, L. E.; Renjifo, B.; McLane, M. F.; Marlink, R.; O'Hara, C.; Sutthent, R.; Wasi, C.; Vithayasai, P.; Vithayasai, V.; Apichartpiyakul, C.; Auewarakul, P.; Cruz, V. P.; Chui, D.-S.; Osathanondh, R.; Mayer, K.; Lee, T.-H.; and Essex, M. 1996, "HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV," Science, Vol. 271, No. 5253, pp. 1291-1293.
39. Travers, K.; Mboup, S.; Marlink, R.; Guèye-Ndiaye, A.; Siby, T.; Thior, I.; Traore, I.; Dieng-Sarr, A.; Sankalé, J.-L.; Mullins, C.; Ndoye, I.; Hsieh, C.-C.; Essex, M.; and Kanki, P. 1995, "Natural protection against HIV-1 infection provided by HIV-2," Science, Vol. 268, No. 5217, pp. 1612-1615.
40. Verani, P.; Buttò, S.; Taddeo, B.; Federico, M.; and Rossi, G. B. 1993, ̀HIV variability and perspectives for a vaccine,̀ Vaccine, Vol. 11, No. 5, pp. 542-544.
41. WHO network for HIV isolation and characterization 1994, ̀HIV Type 1 variation in World Health Organization-sponsored vaccine evaluation sites: Genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains,̀ AIDS Research and Human Retroviruses, Vol. 10, No. 11, pp. 1327-1343.